hydroxyurea has been researched along with Cerebral Ischemia in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect." | 7.80 | Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014) |
| "5-Lipoxygenase inhibitor zileuton has been demonstrated to attenuate ischemic brain damage in rats of permanent focal cerebral ischemia in previous work." | 7.76 | Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. ( Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL, 2010) |
| "Ischemic stroke is characterized by high morbidity, disability, and mortality." | 5.91 | Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke. ( Hong, Y; Hu, F; Jin, X; Ke, J; Li, S; Shang, X; Wang, K; Wen, L; Wu, X; Xu, Y; Yuan, H; Zhou, W, 2023) |
| " In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect." | 3.80 | Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014) |
| " He was thought to have had an embolic stroke and was initially treated with warfarin." | 3.80 | Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014) |
| "To determine 5-lipoxygenase (5-LOX) expression and the effect of zileuton, a selective 5-LOX inhibitor,on hippocampal neuron injury induced by global cerebral ischemia in rats." | 3.79 | [Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats]. ( Chen, W; Han, H; Li, C; Wei, E; Zhang, L; Zhang, X; Zhao, J, 2013) |
| "5-Lipoxygenase inhibitor zileuton has been demonstrated to attenuate ischemic brain damage in rats of permanent focal cerebral ischemia in previous work." | 3.76 | Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. ( Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL, 2010) |
| "Ischemic stroke is characterized by high morbidity, disability, and mortality." | 1.91 | Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke. ( Hong, Y; Hu, F; Jin, X; Ke, J; Li, S; Shang, X; Wang, K; Wen, L; Wu, X; Xu, Y; Yuan, H; Zhou, W, 2023) |
| "The Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) trials established routine transcranial Doppler ultrasound (TCD) screening, with indefinite chronic red cell transfusions (CRCT) for children with abnormal TCD as standard of care." | 1.51 | Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. ( Adams, RJ; Brown, L; Debenham, E; Fullerton, HJ; Kanter, J; Kwiatkowski, JL; Voeks, JH, 2019) |
| "Adult male Sprague-Dawley rats underwent middle cerebral artery occlusion (MCAO), then received treatment with zileuton or vehicle after the onset of ischemia." | 1.43 | 5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway. ( Chen, CM; Liang, RS; Shi, SS; Tu, XK; Wang, CH; Yang, WZ; Zhang, HB, 2016) |
| "Oral treatment of zileuton at 10 or 50 mg/kg significantly reduced cerebral water content and infarct volume." | 1.35 | 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. ( Chen, CM; Shi, SS; Tu, XK; Wang, CH; Yang, WZ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, K | 1 |
| Zhou, W | 1 |
| Jin, X | 1 |
| Shang, X | 1 |
| Wu, X | 1 |
| Wen, L | 1 |
| Li, S | 1 |
| Hong, Y | 1 |
| Ke, J | 1 |
| Xu, Y | 1 |
| Yuan, H | 1 |
| Hu, F | 1 |
| Kwiatkowski, JL | 1 |
| Voeks, JH | 1 |
| Kanter, J | 1 |
| Fullerton, HJ | 1 |
| Debenham, E | 1 |
| Brown, L | 1 |
| Adams, RJ | 1 |
| Guilliams, KP | 1 |
| Fields, ME | 1 |
| Dowling, MM | 1 |
| Boucher, AA | 1 |
| Gurunathan, A | 1 |
| Taylor, JM | 1 |
| Ricci, KW | 1 |
| Vadivelu, S | 1 |
| Quinn, CT | 1 |
| Chen, W | 1 |
| Li, C | 1 |
| Zhao, J | 1 |
| Zhang, X | 1 |
| Han, H | 1 |
| Wei, E | 1 |
| Zhang, L | 1 |
| Ballas, SK | 1 |
| Martinez, U | 1 |
| Savage, M | 1 |
| Tu, XK | 3 |
| Zhang, HB | 1 |
| Shi, SS | 3 |
| Liang, RS | 1 |
| Wang, CH | 3 |
| Chen, CM | 3 |
| Yang, WZ | 3 |
| Biraboneye, AC | 1 |
| Madonna, S | 1 |
| Maher, P | 1 |
| Kraus, JL | 1 |
| Zhang, YL | 1 |
| Yang, YK | 1 |
| Jin, CD | 1 |
| Wen, S | 1 |
| Jordan, LC | 1 |
| Casella, JF | 1 |
| DeBaun, MR | 1 |
| Verdure, P | 1 |
| Lefaucheur, R | 1 |
| Guegan-Massardier, E | 1 |
| Triquenot-Bagan, A | 1 |
| Gerardin, E | 1 |
| Maltête, D | 1 |
| Naganuma, M | 1 |
| Isoda, K | 1 |
| Nishi, S | 1 |
| Ito, K | 1 |
| Hirano, T | 1 |
| Fang, SH | 1 |
| Lin, KN | 1 |
| Huang, XQ | 1 |
| Lu, YB | 1 |
| Zhang, WP | 1 |
| Wei, EQ | 1 |
| Brousse, V | 1 |
| Gandhi, S | 1 |
| de Montalembert, M | 1 |
| Height, S | 1 |
| Dick, MC | 1 |
| O'Driscoll, S | 1 |
| Abihsera, G | 1 |
| Rees, DC | 1 |
| Schmugge, M | 1 |
| Frischknecht, H | 1 |
| Yonekawa, Y | 1 |
| Baumgartner, RW | 1 |
| Boltshauser, E | 1 |
| Humbert, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial[NCT00072761] | Phase 3 | 196 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI. (NCT00072761)
Timeframe: From study entry to study exit
| Intervention | infarct recurrence per 100 person years (Number) |
|---|---|
| Transfusion Group | 2.0 |
| Observation Group | 4.8 |
2 reviews available for hydroxyurea and Cerebral Ischemia
| Article | Year |
|---|---|
Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.
Topics: Acute Disease; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Arteries; Cerebrovas | 2019 |
Prospects for primary stroke prevention in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Transfusion; Brain | 2012 |
14 other studies available for hydroxyurea and Cerebral Ischemia
| Article | Year |
|---|---|
Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Ischemia; Endothelial Cells; Hydroxyurea; Hypoxia; Ischem | 2023 |
Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era.
Topics: Adolescent; Anemia, Sickle Cell; Brain Ischemia; Child; Child, Preschool; Combined Modality Therapy; | 2019 |
Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia.
Topics: Aspirin; Brain Ischemia; Child; Female; Hemoglobinopathies; Hemoglobins, Abnormal; Humans; Hydroxyur | 2019 |
[Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats].
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain Ischemia; CA1 Region, Hippocampal; Disease Models, Anima | 2013 |
Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Ischemia; Echocardiography, Transesophageal; | 2014 |
5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Brain Ischemia; Hydroxyurea; Infarction, Middle Cerebra | 2016 |
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Topics: Animals; Arachidonate 5-Lipoxygenase; Body Water; Brain; Brain Edema; Brain Ischemia; Dose-Response | 2009 |
Neuroprotective effects of N-alkyl-1,2,4-oxadiazolidine-3,5-diones and their corresponding synthetic intermediates N-alkylhydroxylamines and N-1-alkyl-3-carbonyl-1-hydroxyureas against in vitro cerebral ischemia.
Topics: Animals; Brain Ischemia; Cell Line; Extracellular Signal-Regulated MAP Kinases; Hydroxylamines; Hydr | 2010 |
Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Brain; Brain Ischemia; Cerebral Infarction; Di | 2010 |
Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Brain Ischemia; Diplopia; Female; Humans; Hydroxyurea; | 2012 |
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic | 2014 |
Nuclear translocation of cysteinyl leukotriene receptor 1 is involved in oxygen-glucose deprivation-induced damage to endothelial cells.
Topics: Apoptosis; Brain Ischemia; Cell Culture Techniques; Cell Hypoxia; Cell Line; Cell Membrane; Cell Nuc | 2012 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |
Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery.
Topics: Anemia, Sickle Cell; Aphasia; Blood Flow Velocity; Blood Transfusion; Brain Damage, Chronic; Brain I | 2001 |